Documentation scienceplus.abes.fr version Bêta

À propos de : Immunohistochemical Study of Estradiol, Epidermal Growth Factor, Transforming Growth Factor Alpha and Epidermal Growth Factor Receptor in Endometrial Neoplasia        

AttributsValeurs
type
Is Part Of
Subject
Title
  • Immunohistochemical Study of Estradiol, Epidermal Growth Factor, Transforming Growth Factor Alpha and Epidermal Growth Factor Receptor in Endometrial Neoplasia
has manifestation of work
related by
Author
Abstract
  • In a total of 113 cases of endometrial neoplasm, we studied the immunohistochemical expression of estradiol (E2), epidermal growth factor (EGF), transforming growth factor alpha (TGFα), and epidermal growth factor receptor (EGFR). Positive immunoreactivity of E2 was found in 61% of the neoplasms. E2 immunoreactivity correlated well with high histologic grade and early clinical stage. Positive immunoreactivity for ECF or ECFR was found in 25.6% or 53.1% of the neoplasms, respectively. However, this was unrelated to histologic grade or clinical stage. On the other hand, TGFα immunoreactivity was found in 67% of endometrial neoplasias and was correlated with poor histologic grade and advanced stage. Contingency tables indicated a significant negative association between the status of E2 and that of TGFα. Simultaneous expression of E2, EGF and EGFR, or E2, TGFα and EGFR was found in 6.8% and 15.9% of endometrial carcinomas, respectively. These results suggest that a predominant number of endometrial carcinomas escape autocrine/paracrine growth regulation by EGF and E2 or TGFα and E2, and that TGFα may be involved in the progression of endometrial carcinoma.
article type
publisher identifier
  • 26.6.411
is part of this journal



Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata